Thomas M Suter

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi request reprint Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial
    Thomas M Suter
    Swiss Cardiovascular Center, University Hospital Bern, Inselspital, Bern, Switzerland
    J Clin Oncol 25:3859-65. 2007
  2. doi request reprint Cancer drugs and the heart: importance and management
    Thomas M Suter
    Department of Cardiology, Bern University Hospital, 3010 Bern, Switzerland
    Eur Heart J 34:1102-11. 2013
  3. doi request reprint Cancer therapy-associated cardiotoxicity and signaling in the myocardium
    Christian Zuppinger
    Swiss Cardiovascular Center, Inselspital, Bern University Hospital, Bern, Switzerland
    J Cardiovasc Pharmacol 56:141-6. 2010
  4. doi request reprint Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes
    Laura Pentassuglia
    Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland
    Exp Cell Res 315:1302-12. 2009
  5. doi request reprint Cancer therapy modulates VEGF signaling and viability in adult rat cardiac microvascular endothelial cells and cardiomyocytes
    Manuel Chiusa
    Bern University Hospital, Cardiology, CH 3010 Bern, Switzerland
    J Mol Cell Cardiol 52:1164-75. 2012
  6. doi request reprint Effects of doxorubicin cancer therapy on autophagy and the ubiquitin-proteasome system in long-term cultured adult rat cardiomyocytes
    Polychronis Dimitrakis
    Cardiology, Swiss Cardiovascular Center Bern, Bern University Hospital and University of Bern, Bern, Switzerland
    Cell Tissue Res 350:361-72. 2012
  7. pmc The role of cell death and myofibrillar damage in contractile dysfunction of long-term cultured adult cardiomyocytes exposed to doxorubicin
    Francesco Timolati
    Swiss Cardiovascular Center, Inselspital, Bern University Hospital, 3010, Bern, Switzerland
    Cytotechnology 61:25-36. 2009
  8. ncbi request reprint Pathophysiology and diagnosis of cancer drug induced cardiomyopathy
    Christian Zuppinger
    Swiss Cardiovascular Center Bern, Cardiology, Inselspital, University Hospital, 3010 Bern, Switzerland
    Cardiovasc Toxicol 7:61-6. 2007

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial
    Thomas M Suter
    Swiss Cardiovascular Center, University Hospital Bern, Inselspital, Bern, Switzerland
    J Clin Oncol 25:3859-65. 2007
    ..The purpose of this analysis was to investigate trastuzumab-associated cardiac adverse effects in breast cancer patients after completion of (neo)adjuvant chemotherapy with or without radiotherapy...
  2. doi request reprint Cancer drugs and the heart: importance and management
    Thomas M Suter
    Department of Cardiology, Bern University Hospital, 3010 Bern, Switzerland
    Eur Heart J 34:1102-11. 2013
    ..This review discusses concepts for timely diagnosis, intervention, and surveillance of cancer patients undergoing treatment, and provides approaches to clinical uncertainties...
  3. doi request reprint Cancer therapy-associated cardiotoxicity and signaling in the myocardium
    Christian Zuppinger
    Swiss Cardiovascular Center, Inselspital, Bern University Hospital, Bern, Switzerland
    J Cardiovasc Pharmacol 56:141-6. 2010
    ..Subsequently, the role of endothelial-myocardial communication in maintaining phenotype and survival of adult cardiomyocytes has increasingly been recognized...
  4. doi request reprint Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes
    Laura Pentassuglia
    Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland
    Exp Cell Res 315:1302-12. 2009
    ..Clinical studies using ErbB2-targeted inhibitors for the treatment of cancer should be designed to include careful monitoring for cardiac dysfunction...
  5. doi request reprint Cancer therapy modulates VEGF signaling and viability in adult rat cardiac microvascular endothelial cells and cardiomyocytes
    Manuel Chiusa
    Bern University Hospital, Cardiology, CH 3010 Bern, Switzerland
    J Mol Cell Cardiol 52:1164-75. 2012
    ..In conclusion, these data suggest that cancer therapy with anthracyclines modulates VEGF-A release and its cellular receptors in CMEC and ARVM, and therefore alters paracrine signaling in the myocardium...
  6. doi request reprint Effects of doxorubicin cancer therapy on autophagy and the ubiquitin-proteasome system in long-term cultured adult rat cardiomyocytes
    Polychronis Dimitrakis
    Cardiology, Swiss Cardiovascular Center Bern, Bern University Hospital and University of Bern, Bern, Switzerland
    Cell Tissue Res 350:361-72. 2012
    ..This mechanism might contribute to the late cardiotoxicity of anthracyclines by accelerated aging of the postmitotic adult cardiomyocytes and to the susceptibility of the aging heart to anthracycline cancer therapy...
  7. pmc The role of cell death and myofibrillar damage in contractile dysfunction of long-term cultured adult cardiomyocytes exposed to doxorubicin
    Francesco Timolati
    Swiss Cardiovascular Center, Inselspital, Bern University Hospital, 3010, Bern, Switzerland
    Cytotechnology 61:25-36. 2009
    ..We propose, that myofibrillar damage contributes to contractile dysfunction prior to cell death in adult cardiomyocytes exposed to clinically relevant concentrations of anthracyclines...
  8. ncbi request reprint Pathophysiology and diagnosis of cancer drug induced cardiomyopathy
    Christian Zuppinger
    Swiss Cardiovascular Center Bern, Cardiology, Inselspital, University Hospital, 3010 Bern, Switzerland
    Cardiovasc Toxicol 7:61-6. 2007
    ....